Semaglutide
Long-acting GLP-1 receptor agonist research compound with 94% homology to native GLP-1.
From · per box of 10 vials
$45
Triple agonist (GLP-1, GIP, glucagon) research compound for metabolic studies — box of 10 vials.
Retatrutide is a triple incretin receptor agonist targeting GLP-1, GIP, and glucagon receptors, used as a leading reference compound in metabolic research. Priced per box of 10 vials. For laboratory research use only.
Simultaneous activation of GLP-1, GIP, and glucagon receptors enhances energy expenditure signals alongside appetite regulation.
Phase 2 trials reported notable weight reduction at 24 weeks; a reference triple-agonist in incretin research.
Potent investigational compound for laboratory use only. Follow strict handling and reconstitution protocols.
From $180
per box of 10 vials
| Code | Dose | Price (USD) | Actions |
|---|---|---|---|
| RT10 | 10 mg | $180 | |
| RT20 | 20 mg | $285 | |
| RT30 | 30 mg | $345 |
Research Use Only: All products are strictly intended for laboratory research and scientific analysis only. Not for human consumption, clinical use, or diagnostic applications.
Long-acting GLP-1 receptor agonist research compound with 94% homology to native GLP-1.
From · per box of 10 vials
$45
First-in-class dual GIP/GLP-1 receptor agonist for metabolic research.
From · per box of 10 vials
$55
Triple agonist (GLP-1, GIP, glucagon) research compound for metabolic studies.
From · per box of 10 vials
$100
Dual GLP-1/glucagon receptor agonist research compound.
From · per box of 10 vials
$355